AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04281108 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Esophagogastroduodenoscopy
Description: Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus.
Study NCT02812329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV prevention videogame
Description: Assess acceptability and efficacy of a HIV prevention videogame
Study NCT01858506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: I-ACE intervention
Description: lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
Study NCT01858506 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lifestyle Advice
Description: lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
Study NCT01950741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.
Study NCT01435200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous iron
Description: Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy
Study NCT01435200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous iron
Description: Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy
Study NCT05127668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airglove (TM)
Description: A sterile polythene-balloon was inflated around the forearm using the AirGloveTM to 38.5oC at setting number-3 for 3 minutes, then removed and the degree of venodilation assessed by ultrasound.
Study NCT05127668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warm-water Immersion
Description: The upper limbs (to the level of mid-humerus) of participants were immersed in a container filled with a mix of cold-and warm tap-water to 38.5oC for 3 minutes in the WWI method. Arms were towel-dried, and the degree of venodilation was assessed by ultrasound
Study NCT04336085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: caudal block
Description: Caudal block will be performed using ultrasound guidance, the sacral hiatus will be visualized at the level of the sacral cornus by employing the linear transducer of ultrasound machine the ultrasound transducer will be rotated to 90 degree to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the two cornua. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament.
Study NCT04336085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pericapsular nerve group block
Description: In PENG group, the patient will be placed in supine position. The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. A 22-gauge, 50-mm needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, a total volume of 0.5 mL/kg local anesthetic solution will be injected.
Study NCT03121638 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX
Description: Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
Study NCT03121638 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ZOSTAVAX
Description: Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
Study NCT03121638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP6081
Description: Preparation of Oka/SK strain of live, attenuated varicella zoster virus
Study NCT03121638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP6082
Description: Preparation of Oka/SK strain of live, attenuated varicella zoster virus
Study NCT03121638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP6083
Description: Preparation of Oka/SK strain of live, attenuated varicella zoster virus
Study NCT03191994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: a structured, supervised eight week moderate intensity exercise intervention
Study NCT04859361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldara 5% Topical Cream
Description: 5% Imiquimod cream (1 sachet) will be administered via menstrual cup, before going to sleep, 3 times per week for 16 weeks. Menstrual cup will be inserted in the vagina for a duration of 6-8 hours. In case of severe side effects applications can be reduced to twice per week and if side effects are persistent, to once per week. For maximum control of cervical disease, control colposcopy with a PAP smear and a punch biopsy will be scheduled at 10 weeks to rule out progression, and at 20 weeks after treatment initiation to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present, and if there are any new lesions present, additional biopsies will be performed. In case of disease progression or persistence, treatment with LLETZ will be offered.
Study NCT04859361 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLETZ
Description: LLETZ will be performed in an outpatient setting with local anesthesia, using KLS Martin Maxium with loop devices ranging from 10 mm to 20 mm in size. The excision will be performed using monopolar current with a cut frequency set to 100-150 W. Treatment success will be evaluated in accordance with our national guidelines 24 weeks after the procedure using a PAP smear with or without a punch biopsy.
Study NCT00268593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI-88
Description: Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
Study NCT00086827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV
Study NCT00268593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
Study NCT00268593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 5 mg twice a day orally
Study NCT00086827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04945005 — intervention group
Intervention type: PROCEDURE
Intervention: Transesophageal guidance of lead implantation
Description: In patients undergoing lead implantation including transesophageal echocardiography for clinical reasons (e.g. intraprocedural cardioversion), echocardiography was also used for guidance of lead implantation to reduce lead-leaflet interactions
Study NCT03237949 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone counseling
Description: Four telephone counseling sessions using a motivational interviewing approach
Study NCT03930797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intimacy Enhancement
Description: The IE intervention is grounded in cognitive behavioral couple therapy and sex therapy, and includes education and skills training with a focus on the following major topics: understanding effects of breast cancer on sex and intimacy; goal-setting; communication skills; problem-solving and engaging in activities to build intimacy; identifying and restructuring negative or inflexible thoughts; and planning ahead and preparing for challenges. Participants will be asked to participate in written and behavioral activities at home between sessions to strengthen skills acquisition.
Study NCT03930797 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living Healthy Together
Description: The Living Healthy Together (LHT) intervention focuses on delivering education and support to breast cancer survivors and their partners across a range of topics including social support, sleep and fatigue, stress and stress management, nutrition, and physical activity. Participants will be asked to engage actively with the material and to review readings and intervention material between sessions.
Study NCT03200860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: 10 mg daily, oral, 30 days
Study NCT03200860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Matching Placebo, 10 mg daily, oral, 30 days
Study NCT01322139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spray and oral moxifloxacin placebo
Description: 24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
Study NCT01322139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex spray and oral moxifloxacin placebo
Description: 8 Sativex sprays (4 sprays twice daily every 12 hours) + 16 or 28 placebo sprays (8 or 14 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
Study NCT01322139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex spray and oral moxifloxacin placebo
Description: 24 or 36 Sativex sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
Study NCT01322139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo spray and moxifloxacin
Description: 24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
Study NCT02261155 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hypnosis
Description: hypnotic Relaxation without specific analgesic suggestion
Study NCT02590614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 800 IU Vitamin D
Description: Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the intervention group.
Study NCT03237949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message
Description: 30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages follows the self efficacy theory. The messages follows the self efficacy theory.
Study NCT02590614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the placebo group
Study NCT02872194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987516, Y55-170
Description: 10 uL in one eye
Study NCT02872194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987516, X72-151
Description: 10 uL in one eye
Study NCT02872194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987516, Y49-034
Description: 10 uL in one eye
Study NCT02872194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard shampoo mixture (control)
Description: 10 uL in one eye
Study NCT01858298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative treatment: pulpectomy and composite resin crown
Study NCT01858298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-conservative treatment: Tooth extraction
Study NCT00033449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study NCT00033449 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00033449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00033449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00357786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Replagal agalsidase alfa
Study NCT00357786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Replagal
Study NCT00995189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opti-Free RepleniSH
Description: Contact lens care solution containing polyquaternium-1 (PQT)
Study NCT00995189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus
Description: Contact lens care solution containing polyhexamethylene biguanide (PHMB)
Study NCT00995189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lenses
Description: Daily wear, frequent replacement contact lenses per participant's habitual brand and power.
Study NCT00995189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lenses
Description: Daily wear, frequent replacement contact lenses per participant's habitual brand and power.
Study NCT04311437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-acupressure therapy
Description: The self-acupressure therapy is as follows: Patients are in sitting position, applied firm pressure (3-5 kg of pressure) with the fingertips in a circular motion at a speed of two circles per second for a duration of one min per acupoint. A 1-2-s rest is applied after each ten circles. The complete process lasts for about 5 min.
Study NCT04311437 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Combined Valsalva and Toynbee maneuvers
Description: Valsalva maneuver: blowing against a closed mouth and nostrils, increasing the middle ear pressure. Toynbee maneuver: swallowing while the mouth and nostrils are closed, decreasing the middle ear pressure.
Study NCT04311437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Valsalva and Toynbee maneuvers
Description: Valsalva maneuver: blowing against a closed mouth and nostrils, increasing the middle ear pressure. Toynbee maneuver: swallowing while the mouth and nostrils are closed, decreasing the middle ear pressure.
Study NCT03637894 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Feeding infants with fermented formula milk
Description: Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
Study NCT03637894 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Feeding infants with standard formula milk
Description: Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
Study NCT03637894 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Breastfeeding infants
Description: Reference group
Study NCT01695863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: comparing 2 drugs on their effect on the bowel preparation for colonoscopy
Description: the effects of the drug on the colon preparation for colonoscopy
Study NCT01437943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Take 1 tablet (150 mg) by mouth daily for 180 days
Study NCT01437943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 1 tablet (0 mg) daily for 180 days.
Study NCT03102463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Water Control
Description: 120mL water given as a control, followed by a hyperinsulinemic-euglycaemic clamp
Study NCT03102463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk derived hydrolysate
Description: Milk derived hydrolysate made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
Study NCT03102463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parent Protein
Description: Parent protein made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
Study NCT03102463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lipid Load
Description: 100mL oral lipid load
Study NCT03102463 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lipid Load
Description: 100mL oral lipid load
Study NCT01577628 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lipikar Balm AP
Description: Daily application of Lipikar Balm AP starting at birth
Study NCT03250130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypnosis
Description: The patient achieve self-hypnosis sessions in these chemotherapy treatments
Study NCT01751789 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Linkage
Study NCT01751789 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Study NCT01512693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0822
Description: A single oral dose (50 mg tablet) of MK 0822 will be administered on Day 1 after an overnight fast.
Study NCT01058057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: atorvastatin 80mg p.o. daily seven days before PCI
Study NCT03317912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaïne 2%
Description: Continuous infusion during per and postoperative periods
Study NCT03317912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Lidocaïne)
Description: Continuous infusion during per and postoperative periods
Study NCT02823613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High salt diet followed by low salt diet
Description: High salt diet (250 mmol/day) in 5 days followed by low salt diet (60-70 mmol/day) in 5 days.
Study NCT02823613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low salt diet followed by high salt diet
Description: Low salt diet (60-70 mmol/day) in 5 days followed by high salt diet (250 mmol/day) in 5 days.
Study NCT04597515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot Breast reduction surgery
Description: Breast reduction surgery, using a robot by removing a breast disc at the base
Study NCT03077555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoely
Description: quick start of combined hormonal contraception containing 1.5 mg estradiol /2.5 mg nomegestrol acetate
Study NCT03077555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meliane ED
Description: quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene
Study NCT00000259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15 % Nitrous oxide
Study NCT03154190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT03154190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03154190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03154190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Undergo health care coach support
Study NCT03154190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03154190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04086589 — intervention group
Intervention type: OTHER
Intervention: Observational study without intervention
Description: Observational study without intervention
Study NCT03525873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03525873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03525873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Given PO
Study NCT03525873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participate in physical activity
Study NCT03525873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Activity
Description: Participate in physical activity
Study NCT03525873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT03525873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03525873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03525873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03525873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03520790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
Study NCT03520790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.